Autologous Matrixinduced Chondrogenesis Market 2022
In terms of revenue, the global AMIC market is projected to register a CAGR of 8.6% over the forecast period owing to various factors, on which Persistence Market Research offers detailed insights and forecasts. The global Autologous Matrix-Induced Chondrogenesis market value in 2016 is estimated to be US$ 96.11 Mn and this is expected to increase to US$ 186.4 Mn by the end of 2024.
Get Free Sample Copy Of Autologous Matrixinduced Chondrogenesis Market Report@ https://www.persistencemarketresearch.com/samples/12271
Persistence Market Research delivers key insights on the global Autologous Matrix-Induced Chondrogenesis (AMIC) Market in its published report titled, “Global Market Study on Autologous Matrix-Induced Chondrogenesis (AMIC): Polyethylene Glycol (PEG) Segment Expected to Grow with a Healthy CAGR over the Forecast Period ”. In terms of revenue, the global AMIC market is projected to register a CAGR of 8.6% over the forecast period owing to various factors, on which Persistence Market Research offers detailed insights and forecasts. The global Autologous Matrix-Induced Chondrogenesis market value in 2016 is estimated to be US$ 96.11 Mn and this is expected to increase to US$ 186.4 Mn by the end of 2024.
Autologous Matrix-Induced Chondrogenesis (AMIC) is a biological treatment method to repair articular cartilage damage. AMIC therapy is a step wise process. Micro fracture surgery is followed by application of a bi-layer collagen I/III membrane. It slows down cartilage degeneration with an intent to avoid or delay partial or total joint replacement (e.g. knee replacement) surgery. The indications for AMIC includes Grade III or IV chondral lesions with lesion size of about 2 cm2 to 8cm2.
Company Profiles:
- Anika Therapeutics, Inc.
- Arthro-Kinetics
- B. Braun Melsungen AG
- BioTissue AG
- CartiHeal
- Geistlich Pharma AG
- JRI Orthopaedics Ltd.
- Matricel GmbH
- Smith & Nephew plc
- Zimmer Biomet Holdings
Look Through The “Methodology” Employed@ https://www.persistencemarketresearch.com/methodology/12271
Autologous Matrix-Induced Chondrogenesis (AMIC) is a biological treatment method to repair articular cartilage damage. AMIC therapy is a step wise process. Micro fracture surgery is followed by application of a bi-layer collagen I/III membrane. It slows down cartilage degeneration with an intent to avoid or delay partial or total joint replacement (e.g. knee replacement) surgery. The indications for AMIC includes Grade III or IV chondral lesions with lesion size of about 2 cm2 to 8cm2.
Market dynamics
The growth of the global Autologous Matrix-Induced Chondrogenesis market is mainly driven by increasing demand for minimally invasive procedures, rising prevalence of bone and joint disorders and a surge in sports injuries. Another prominent growth driver is the faster uptake and access along with affordable pricing. However, lack of clinical data and lack of efficient reimbursement is expected to restrain the growth of the market over the forecast period.
Market forecast
The market is segmented based on material type and regions. Based on the material type, the market is segmented into Hyaluronic Acid, Collagen, Polyethylene glycol (PEG), polylactic-co-glycolic acid (PGLA) and others. The PEG segment is expected to grow at a healthy CAGR over the forecast period, owing to its ability to be gelled into complex defects in situ using UV-light.
he segment is expected to register a significant CAGR of 11.1 % during the forecast period. The Others segment, which includes PLLA, agarose-alginate, chitosan, poly (ester-ether) polydioxanone, etc. is anticipated to grow at a CAGR of 8.1%. Segments such as hyaluronic acid and collagen are expected to register a CAGR of 8.9% and 8.2% respectively over the forecast period. The PGLA segment is expected to witness a CAGR of 9.2% over the forecast period.
Purchase Our Autologous Matrixinduced Chondrogenesis Market Report Now@ https://www.persistencemarketresearch.com/checkout/12271
This report assesses trends that drive the growth of each segment on the global as well as regional levels and offers potential takeaways that could prove substantially useful to surgical products manufacturing companies that wish to enter the global Autologous Matrix-Induced Chondrogenesis (AMIC) market. North America is anticipated to dominate the global Autologous Matrix-Induced Chondrogenesis (AMIC) market with the maximum market share in 2016.
North America is expected to account for more than 38% of the total Autologous Matrix-Induced Chondrogenesis (AMIC) market share in terms of value in 2016. Followed by North America, Europe is one of the established markets for AMIC. Europe contributes to around 34% of the total market share in 2016. Among emerging markets, Asia Pacific is estimated to exhibit the highest CAGR of 10.3% over the forecast period, due to higher adoption of AMIC procedures in the region.
About Us:
PersistenceMarketResearch is an esteemed company with a reputation of serving clients across domains of information technology (IT), healthcare, and chemicals. Our analysts undertake painstaking primary and secondary research to provide a seamless report with a 360 degree perspective. Data is compared against rep/uted organizations, trustworthy databases, and international surveys for producing impeccable reports backed with graphical and statistical information.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
No comments:
Post a Comment